Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 31447E105 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
| PharmaCyte Biotech, Inc. 13G | 7.9% |
3/18/2026
Event 3/17/2026
|
|
| Dauntless Investment Group, LLC 13G/A Amendment 1 | 9.9% |
11/14/2025
Event 9/30/2025
|
|
|
Alumni Capital LP
13G
|
10.0% |
9/4/2025
Event 9/4/2025
|
|
| Alumni Capital LP | 10.0% | ||
| Alumni Capital GP LLC | 10.0% | ||
| Ashkan Mapar | 10.0% | ||
| Chernett Jorey 13G/A Amendment 1 | 9.3% |
8/5/2025
Event 6/30/2025
|
|
| Chernett Jorey 13G | 6.2% |
2/26/2025
Event 2/19/2025
|
|
| Dauntless Investment Group, LLC 13G | 5.4% |
2/26/2025
Event 2/18/2025
|
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 1 | 750 | $2.00 |
| 2026 Q2 | 2 | 1.75 k | $309.00 |
| 2026 Q1 | 36 | 9.47 M | $3.97 M |
| 2025 Q4 | 38 | 9.46 M | $2.88 M |
| 2025 Q3 | 32 | 3.76 M | $1.33 M |
| 2025 Q2 | 38 | 5.29 M | $3.67 M |
| 2025 Q1 | 31 | 3.90 M | $4.88 M |
| 2024 Q4 | 30 | 2.39 M | $2.62 M |
| 2024 Q3 | 28 | 1.67 M | $1.86 M |
| 2024 Q2 | 30 | 1.64 M | $1.87 M |
| 2024 Q1 | 26 | 1.52 M | $2.36 M |
| 2023 Q4 | 26 | 1.48 M | $1.44 M |
| 2023 Q3 | 29 | 1.69 M | $6.56 M |
| 2023 Q2 | 23 | 1.29 M | $4.37 M |
| 2023 Q1 | 20 | 1.30 M | $3.40 M |
| 2022 Q4 | 20 | 1.07 M | $2.45 M |
| 2022 Q3 | 18 | 894 k | $1.01 M |
| 2022 Q2 | 19 | 832 k | $2.00 M |
| 2022 Q1 | 18 | 822 k | $1.86 M |
| 2021 Q4 | 17 | 519 k | $2.02 M |
| 2021 Q3 | 11 | 523 k | $3.61 M |
| 2021 Q2 | 12 | 601 k | $4.90 M |